Ok, so let's assume our microfluidic sensor works in with other components/sensors with IBM CMOS IP applied. Now to reflect on the NanoDX release and our last quarterly. It's hard not to be bullish about NanoDX again.
From the last quarterly :
NanoDiagnostics Incorporated (NanoDX) has continued to have challenges with releasing their SARS-CoV-2 detection system. This has slowed progress towards volume production. Notwithstanding, Sensera has been asked to start the ramp of sensors in Q1 of FY22. This ramp is still predicated on FDA approval through the Emergency Use Authorization (EUA) process. As previously disclosed, there is a risk that NanoDX may not satisfy the FDA’s requirements for an EUA and/or the evaluation of NanoDX’s EUA submission may take longer than expected.
So, IMO this makes sense now. NanoDX were in a NDA with IBM working towards resolving issues. Telling Sensera get ready, volume ramp in July-Sept, but can't you why ... just trust us.
And now we know what they were working towards. IBM CMOS technology to the rescue.
And in the interview above Sharad is now confident enough to say :
- The company will likely achieve EUA status for its platform within the next two months, said Joshi. - “That's just for COVID-19 and if those levels of accuracy and the mechanism of action remain the same for other areas, it's very likely that we could put a big dent in the POC market,” Joshi said.
In the article :
- would allow it to achieve its goals of mass-producing the tens of millions of units needed to meet the projected demand.
So, the $10M "covid sensor" indicative order from the SE1 AGM is starting to look possible again, de-risked from this IBM development. And definitely not in the SP.
Actually looking forward to the quarterly now ....
IMO GLTAH
SE1 Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
